Compactin Technology

1. Product Presentation

Trivial names:  Compactin, ML-236B

Generic name  (USAN) - MEVASTATIN

Empirical Formula: C23 H34 O5+

Molecular Weight: 390.52

2. Pharmaceutical Use

Coronary artery disease is an exceptionally important problem in industrial society and is often associated with arteriosclerosis, a condition in which esterified and free cholesterol is deposited in thinner walls of coronary arteries. Extensive epidemiological studies  have established a link between abnormally high blood levels of low density lipoprotein cholesterol and the incidence of coronary arteriosclerosis.

Compactin is a precursor drug, which could be transformed to pravastatin that treats hypercholesterolemia. Pravastatin is the principle metabolite and a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. This enzyme catalyzes the conversion of hydroxymethylglutarate to mevanolate, which is an early and rate limiting step in the biosynthesis of cholesterol.

The effectiveness of pravastatin in lowering cholesterol has been confirmed clinically and it is approved for the treatment of primary hypercholesterolemia.

3. Technology

Strain and technological know-how is available through ITTC

Final titre (expected): 13-15 g/l

Fermentation time: 216-264 hrs

Recovery yield: 70-80%

Purity of product: 90-95%

4. Contact 

Add:    Room 701B/D, Building B, Science Park Tower, Tsinghua Science Park, Haidian District, Beijing 100084, China

Tel:    +86 10 62795180

Fax:    +86 10 62795182 

E-mail:  biotech@ittc.com.cn 

Website: www.coway.com.cn    www.coway-biotech.com